NBC Securities Inc. Has $1.43 Million Stock Holdings in GSK plc (NYSE:GSK)

NBC Securities Inc. trimmed its position in GSK plc (NYSE:GSK) by 1.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,335 shares of the pharmaceutical company’s stock after selling 562 shares during the quarter. NBC Securities Inc.’s holdings in GSK were worth $1,429,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GSK. Hsbc Holdings PLC acquired a new position in GSK in the fourth quarter valued at approximately $92,281,000. Armistice Capital LLC increased its holdings in GSK by 670.5% in the fourth quarter. Armistice Capital LLC now owns 2,196,000 shares of the pharmaceutical company’s stock valued at $81,384,000 after purchasing an additional 1,911,000 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in GSK by 10.8% during the fourth quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock worth $558,330,000 after buying an additional 1,465,165 shares during the last quarter. Provident Trust Co. grew its position in shares of GSK by 53.6% during the 4th quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock worth $137,746,000 after buying an additional 1,297,385 shares during the period. Finally, FMR LLC increased its stake in shares of GSK by 7.7% in the 3rd quarter. FMR LLC now owns 18,099,513 shares of the pharmaceutical company’s stock valued at $656,107,000 after acquiring an additional 1,291,161 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Stock Performance

GSK opened at $40.95 on Thursday. The company has a market capitalization of $84.87 billion, a price-to-earnings ratio of 14.84, a P/E/G ratio of 1.24 and a beta of 0.66. The business’s 50-day moving average price is $42.56 and its two-hundred day moving average price is $41.03. GSK plc has a 1 year low of $33.67 and a 1 year high of $45.92. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.15. GSK had a return on equity of 51.54% and a net margin of 14.62%. The business had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. Equities analysts expect that GSK plc will post 4.11 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be issued a dividend of $0.3762 per share. This is a boost from GSK’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $1.50 annualized dividend and a yield of 3.67%. GSK’s dividend payout ratio is presently 53.26%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GSK. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. The Goldman Sachs Group began coverage on GSK in a research note on Thursday, May 30th. They set a “neutral” rating and a $47.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK has an average rating of “Moderate Buy” and a consensus price target of $47.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.